Jaydess

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jaydess

What is Jaydess?

Jaydess is a long-acting reversible contraceptive (LARC) known as an intrauterine system (IUS). It is a small, T-shaped device made of flexible plastic that is placed within the uterus by a healthcare professional. Once in place, it provides continuous pregnancy prevention for up to three years.

Composition and Mechanism

The device contains a reservoir of levonorgestrel, a progestogen hormone frequently used in various contraceptive methods. Jaydess does not contain estrogen. The system is designed to release a low dose of this hormone directly into the uterine cavity at a consistent rate.

Jaydess prevents pregnancy through several localized actions within the uterus:

  • Thickening of Cervical Mucus: The hormone increases the viscosity of the mucus at the cervix, creating a physical barrier that inhibits sperm from entering the uterus.
  • Inhibition of Sperm Function: The local environment within the uterus and fallopian tubes becomes unfavorable for sperm motility and function, preventing fertilization.
  • Thinning of the Uterine Lining: The hormone keeps the lining of the uterus (endometrium) thin, which may prevent the implantation of a fertilized egg.

Key Characteristics

Unlike oral contraceptives that require daily administration, Jaydess is a long-term method that remains active without daily intervention from the user. It is one of the smallest intrauterine systems available, designed specifically to be suitable for women who have not previously given birth, as well as those who have. Its effectiveness is not influenced by user adherence, such as forgetting to take a pill.

After the three-year period, or if pregnancy is desired sooner, the device must be removed by a healthcare provider. Fertility typically returns to its baseline level promptly after the system is removed.

What side effects are possible with Jaydess ?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of the Levonorgestrel Intrauterine System (Jaydess), as classified in authoritative government regulatory documents.

Frequency-Classified Adverse Reactions

The official safety profile structures potential effects based on their frequency, according to the standard regulatory framework:

  • Very Common (Affecting 1 in 10 users or more): Headache, abdominal or pelvic pain, acne, changes in uterine bleeding patterns (such as amenorrhoea or spotting), and vaginitis.
  • Common (Affecting less than 1 in 10 users): Depressed mood, migraine, nervousness, nausea, back pain, breast pain or tenderness, ovarian cyst formation (functional ovarian cyst), weight increase, and partial or complete device expulsion.
  • Uncommon (Affecting less than 1 in 100 users): Pelvic inflammatory disease (PID), hypersensitivity reactions, and oedema.

Systemic and Serious Safety Patterns

The documented adverse reactions are grouped by the affected System-Organ-Class (SOC), including the Reproductive System, Nervous System, Skin, and Infections. Safety statements explicitly highlight certain risks associated with the timing of use. Changes in bleeding patterns are generally more common in the initial months following insertion, with amenorrhoea often increasing with long-term use. Risks such as Uterine Perforation and Serious Infection (including sepsis) are primarily documented in relation to the insertion procedure.

High-Level Safety Constraints

The official label defines high-level safety constraints that restrict use, including situations like known or suspected pregnancy, current or recurrent Pelvic Inflammatory Disease (PID), unexplained uterine bleeding, and active liver disease or confirmed hormone-sensitive malignancy. These conditions establish the administration-agnostic safety boundaries for the product.

Overdose and Emergency Response

The official regulatory description for the Levonorgestrel Intrauterine System (IUS) overdose emphasizes that a systemic hormonal overdose is very unlikely to occur. This is due to the device's low, localized release rate of the active ingredient directly into the uterine cavity.

In the theoretical case of high systemic exposure to Levonorgestrel, the documented overdose manifestations are generally limited to non-severe symptoms such as nausea and vaginal bleeding (or heavy menstrual bleeding). Treatment for a systemic overdose is confined to symptomatic and supportive measures, as no specific antidote is known for the active ingredient.

The primary focus for emergency medical attention, as mandated by regulatory authorities, centers on the risk of severe, acute device-related complications. These are classified as severe or life-threatening medical emergencies.

When Immediate Medical Help is Required

Immediate medical attention must be sought for signs of severe or life-threatening conditions. Regulator-mandated phrasing requires seeking immediate care for severe pain in the lower abdomen or side, which may indicate complications of an ectopic pregnancy or uterine perforation. Furthermore, emergency services must be contacted immediately if a person collapses, has a seizure, has trouble breathing, or cannot be awakened.

Therapeutic Uses of Jaydess

Jaydess is used across therapeutic domains involving continuous, supportive management of the risk of unplanned pregnancy over a chronic, multi-year timeframe. It provides patients with a form of contraception considered relevant for long-term, reversible use. The system is used for managing reproductive health and offers ancillary supportive relief from symptoms related to the menstrual cycle, including excessive flow and cyclical pelvic discomfort. This may contribute to shorter and lighter periods, helping to ease the overall symptomatic burden. The system is also relevant in specific clinical settings, such as for individuals who have not previously given birth.

“The use is considered relevant for individuals requiring continuous, low-maintenance contraception and supportive symptomatic relief.”

Quick Fact: Relief for Menstrual Symptoms
Symptom Cluster Excessive flow, cyclical pelvic discomfort
Key Benefit Contribution to shorter, lighter periods
Clinical Context Long-term symptomatic management

Eligibility and Restrictions for Use

The official eligibility profile for Jaydess (levonorgestrel 13.5 mg IUS) is primarily defined by the absolute restrictions stated in regulatory labeling. The system is indicated for use in women of childbearing age, including post-menarcheal adolescents.


Absolute Contraindications

The medicine must not be used if any of the following conditions are present, as they are absolute contraindications according to official regulatory documents:

  • Pregnancy or suspected pregnancy.
  • Acute or recurrent Pelvic Inflammatory Disease (PID) or uncontrolled lower genital tract infections.
  • Known or suspected malignancies, including uterine/cervical cancer or progestogen-sensitive tumors like breast cancer.
  • Acute liver disease or liver tumors.
  • Uterine anomalies that distort the uterine cavity or abnormal uterine bleeding of unknown cause.

Use Limitations and Restrictions

Use is subject to limitations in specific populations. Jaydess is not indicated for use before menarche or in postmenopausal women. Its use is not studied in women over the age of 65, or those with non-acute hepatic impairment or renal impairment. Insertion is subject to a minimum six-week delay postpartum. Removal should be considered if severe arterial disease (such as stroke) or focal migraine arises.

What should I know about interactions with other medicines?

Official Interaction Profile

The interaction profile for the Jaydess Levonorgestrel Intrauterine System (IUS) is primarily defined by the metabolism of the active ingredient, Levonorgestrel, via the Cytochrome P450 3A4 (CYP3A4) enzyme system. Co-administration with medicinal products that modulate this enzyme can alter the systemic plasma concentration of Levonorgestrel.

Exposure-Modifying Agents

Certain hepatic enzyme-inducing agents are officially documented to increase the clearance of Levonorgestrel, resulting in reduced plasma levels. These include specific antiepileptics (such as phenytoin, carbamazepine, and phenobarbital) and anti-infectives (such as rifampicin and griseofulvin). The herbal product St. John's wort (Hypericum perforatum) is also explicitly cited in regulatory information as a CYP3A4 inducer that may reduce hormone exposure.

Conversely, strong CYP3A4 inhibitors (such as azole antifungals and certain HIV medications) are documented to potentially increase Levonorgestrel plasma concentration.

Interaction Context and Restrictions

No medicinal products are listed as strictly contraindicated combinations due to a drug-drug interaction risk in the official regulatory documents. Furthermore, the regulatory guidance provides the constraint that the clinical significance of these systemic interactions is considered minimal. This is due to the IUS providing localized drug delivery that maintains a low systemic dose, making a substantial impact on contraceptive efficacy unlikely. No mandatory timing-based separation rules are documented for co-administration.

Mechanism of Action

Local Progesterone Receptor Agonism

Levonorgestrel (LNG) is released locally, achieving maximal concentration within the uterine and cervical tissues. LNG acts as a potent synthetic agonist for the Nuclear Progesterone Receptor (PR). This targeted receptor binding initiates the cellular signaling associated with progestogenic action, maintaining low systemic levels to avoid broadly influencing central hormonal pathways.

Endometrial Suppression and Barrier Formation

Receptor activation causes two primary physiological outcomes: it induces the thinning and atrophy of the endometrium, which alters the uterine lining structure and suppresses the proliferative phase. Simultaneously, it modulates cervical gland function, causing the mucus to become highly viscous and opaque, establishing a physical barrier to sperm transport.

Mechanistic Focus on Peripheral Anti-Fertilization

The mechanism relies predominantly on these peripheral anti-fertilization effects and tissue modulation. Because localized delivery maintains systemic drug levels too low to consistently suppress the central Hypothalamic-Pituitary-Ovarian (HPO) axis), the action is fundamentally based on inhibiting fertilization and implantation, rather than on inhibiting ovulation.

Dosage and Administration Information

The use of Jaydess, an intrauterine delivery system (IUS) containing 13.5 mg of levonorgestrel, is defined by specific procedural and duration-of-use requirements.

Administration Scope

The Jaydess IUS is administered via the Intrauterine route, meaning it is inserted directly into the uterine cavity. The device releases levonorgestrel at a rate of approximately 14 mcg per day after 24 days, declining to about 5 mcg per day after three years.

Procedural Requirements and Timing

Insertion must be performed only by a trained healthcare professional using strict aseptic technique. The device is supplied as a sterile, single-use product.

Timing of Insertion:

  • Standard Insertion: Typically inserted within seven days of the onset of menstruation to ensure the user is not pregnant.
  • Post-Procedural Insertion: Can be inserted immediately following a first-trimester abortion.
  • Postpartum: Insertion must be postponed until the uterus is fully involuted, which is generally a minimum of six weeks after delivery.

Course Duration and Follow-up

  • Duration: The IUS is approved for a continuous course of administration lasting up to three years.
  • Removal/Replacement: The device must be removed or replaced after three years from the date of insertion.
  • Follow-up: Standard clinical protocols involve a re-examination by a healthcare provider 4 to 6 weeks after insertion and then yearly, or more frequently if clinically indicated.

Recent Clinical Evidence

Clinical Research Evidence and Studies Overview

This section summarizes the high-level findings of the official research studies and regulatory evaluations for Jaydess, focusing on the study populations, outcomes measured, and the recognized scope of the evidence.


Evidence for Use in Contraception

The primary evidence base for Jaydess was evaluated in large, multi-center Randomized Controlled Trials (RCTs). The research focused on women of childbearing age to explore pregnancy rates when using the system over a three-year period. Researchers examined pregnancy rates by tracking two main outcomes: the Pearl Index (a measurement of pregnancies per 100 woman-years) and the cumulative failure rate (the overall pregnancy rate over the study duration). Studies reported the measurements of the Pearl Index across the three-year study. Research also described the patterns observed related to device retention—how long users kept the system—over that same time frame.

Evidence for Changes in Menstrual Patterns

Data related to changes in bleeding and spotting patterns was observed in these trials as a secondary outcome. Researchers monitored the change in the average number of bleeding and spotting days over defined periods throughout the three-year trial. Studies described patterns of how symptoms evolved in the observed populations, noting changes in the number of bleeding and spotting days. The 13.5 mg system was not formally studied as a dedicated treatment indication for heavy menstrual bleeding (menorrhagia); the research instead focuses on changes that occur as a pattern observed during contraceptive use.


Research in Special Populations

The main clinical trials was evaluated in specific groups, particularly nulliparous women (those who have not given birth) and adolescents. Nulliparous women made up a significant proportion of the study populations, allowing research to describe patterns related to pregnancy rates and user experience in this group. Specific adolescent studies were also conducted, monitoring the use of the device in post-menarcheal individuals.

Remaining Research Gaps and Uncertainties

Evidence is limited for long-term outcomes, as data from the pivotal trials regarding pregnancy prevention rates beyond the three-year mark are not well characterized. Comparative evidence is lacking from large-scale studies directly comparing the 13.5 mg IUS with the higher-dose 52 mg LNG-IUS for their primary purpose. The research is centered on contraception, but its findings describe group patterns, and research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Jaydess (FAQ)


Q: How is Jaydess different from Kyleena or Mirena?

A: Official product information states that Jaydess contains a lower total dose of the hormone levonorgestrel (13.5 mg) compared to both Mirena (52 mg) and Kyleena (19.5 mg). Jaydess is also approved for a shorter duration of use, lasting up to three years. Its smaller size and lower hormone level are descriptive features that position it differently among similar intrauterine systems in clinical consideration.

Q: Does Jaydess contain estrogen?

A: No. According to regulatory documents, Jaydess is classified as a Progestogen-only contraceptive. The only active ingredient is levonorgestrel, which is a synthetic progestogen, and the device does not contain any estrogen.

Q: What is the size of the Jaydess device?

A: The flexible T-shaped frame of the Jaydess device measures approximately 28 mm in width and 30 mm in length. Official information notes that this smaller size is a design feature sometimes considered in clinical assessment for a wider range of users.

Q: Can Jaydess be used by women who have not given birth?

A: Yes. Official eligibility documents indicate that Jaydess is suitable for use in women of childbearing age, which includes those who have not given birth (referred to as nulliparous women) and post-menarcheal adolescents. This evidence from clinical trials is used to describe its profile within this population.

Q: Can I use tampons or a menstrual cup with Jaydess?

A: Official documentation does not specify restrictions for tampons in most cases. While menstrual cups are not prohibited, patient instructions advise caution. To minimize the risk of dislodgement, care should be taken to avoid pulling on the threads when removing a cup.

Q: How does the amount of hormone in Jaydess compare to the pill?

A: Jaydess delivers the hormone levonorgestrel primarily locally within the uterus. Because of this targeted delivery, the amount of the hormone circulating in the rest of the body is significantly lower than the systemic levels found with most daily oral contraceptive pills. This low systemic level is confirmed by pharmacokinetic data in regulatory documents.

Q: Can Jaydess be felt during intercourse?

A: The main part of the Jaydess device is placed high inside the uterus and should not be felt by the user or their partner. A partner may occasionally feel the flexible threads that extend through the cervix. If the threads cause persistent discomfort, their position or length can be checked by a healthcare professional.

Q: How is Jaydess different from the copper IUD?

A: Jaydess is classified as a hormonal system because it releases the synthetic hormone levonorgestrel. In contrast, the copper IUD (Intrauterine Contraception) is non-hormonal, preventing pregnancy through a local reaction to copper. As a result, research describes that Jaydess use is typically associated with lighter menstrual bleeding.

Q: What are the most common reasons people choose Jaydess?

A: Jaydess is selected as a highly effective form of Long-Acting Reversible Contraception (LARC) that provides continuous protection for up to three years. Its features of a low hormone dose and smaller size are frequently considered in the context of nulliparous women and adolescents, according to clinical research.

Q: What is the difference between Jaydess and Skyla?

A: Jaydess (used in Europe and other regions) and Skyla (used in the United States) are the same product marketed under different brand names. Both systems contain 13.5 mg of levonorgestrel and are approved for up to three years of contraceptive use.

Q: Can Jaydess be used while breastfeeding?

A: Yes. Regulatory guidance and official information state that levonorgestrel intrauterine systems are an acceptable contraceptive option for people who are breastfeeding. Insertion, however, is subject to the rule that it should be postponed until at least six weeks after delivery.

Q: What if the strings of Jaydess seem shorter or longer than before?

A: Patient instructions explain that a noticeable change in the length of the threads, or the inability to feel them at all, may indicate that the device has moved out of its correct position. If this occurs, regulatory guidance suggests using a back-up method of contraception and having a healthcare professional check the system’s location.

Q: Do studies suggest Jaydess can cause acne?

A: Yes. According to the official safety profile provided in regulatory documents, acne is listed as a Very Common side effect. This means that, in clinical studies, acne was reported as a common change experienced by users.

Q: Is it possible to become pregnant right after Jaydess is removed?

A: Yes. A key feature of the Jaydess system is that the contraceptive effect stops quickly upon removal. Regulatory information confirms that fertility returns rapidly, meaning pregnancy is possible as soon as the first cycle after the device is taken out.

Q: What kind of follow-up care is generally suggested after getting Jaydess?

A: Official regulatory guidance requires a follow-up examination by a healthcare provider 4 to 6 weeks after the initial insertion to confirm the correct position of the device. After that, yearly re-examinations are required, or more frequently if a specific clinical concern arises.

Q: What research exists about the satisfaction levels of Jaydess users?

A: Clinical study programs included observational research focused on assessing user satisfaction and quality of life (QoL) with the Jaydess system. These studies described favorable user satisfaction rates related to the system’s convenience and effectiveness as a long-acting method.

Q: How often do people report feeling the strings of Jaydess?

A: Patient guidance recommends checking the strings regularly, though the ability to feel them varies widely among users. Official regulatory documentation does not provide statistics on the frequency with which users report feeling the strings, but recommends a healthcare check if the strings feel different.

How should Jaydess be stored and disposed of?

Jaydess is an Intrauterine Delivery System (IUS) for professional use that requires strict adherence to labeled storage and disposal rules to maintain its integrity and protect the environment.

Official Storage Requirements

Condition Regulatory Rule
Temperature Store at a temperature not above 30,^circmathrmC (86,^circmathrmF). Do not refrigerate or freeze.
Protection Keep in the original sealed blister pack and outer carton to protect the system from light and moisture.
Security The product must be kept out of the sight and reach of children.

Official Disposal Instructions

Disposal must follow specific pharmaceutical waste guidelines. The device should not be disposed of via household waste or wastewater (e.g., sink or toilet). Any unused or expired Jaydess system must be returned to a pharmacist or collected according to local requirements for proper environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Jaydess  found in:

A-Z Index: